Estimated total direct and indirect costs per patient over 5 years
| HER2−/HR+ | HER2+/HR+ | HER2+/HR− | Triple negative | Average | |
| Direct costs | |||||
| Active treatment | 20 366 € | 150 131 € | 147 784 € | 26 506 € | 58 664 € |
| Toxicity management | 1251 € | 1725 € | 1703 € | 1873 € | 1492 € |
| Diagnostic | 2546 € | 2562 € | 2545 € | 2433 € | 2529 € |
| Medical follow-up | 18 678 € | 24 444 € | 22 578 € | 14 163 € | 19 361 € |
| Palliative/BSC costs | 77 595 € | 111 167 € | 74 276 € | 49 434 € | 78 359 € |
| Total direct costs | 1 204 376 € | 290 029 € | 248 885 € | 94 409 € | 160 405 € |
| Indirect costs | 227 € | 317 € | 266 € | 164 € | 237 € |
| Total direct and indirect costs | 120 664 € | 290 346 € | 249 152 € | 94 572 € | 160 642 € |
BSC, best supportive care; HER2, human epidermal growth factor receptor 2; HR, hormonal receptor.